Mencuro Therapeutics Inc is categorized under Business Services (Unclassified) in Lawrence, KS and active since 2010.
Mencuro Therapeutics Inc was established in 2010, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Business Services (Unclassified) business, which does work in the B2B market, and is classified as a Business Services (Unclassified), under code number 561499 by the NAICS.
If you are seeking more information, feel free to contact Robert Karr at the company’s single location by writing to 917 Diamondhead Drive, Lawrence, Kansas KS 66049 or by phoning (860) 938-2315. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Mencuro Therapeutics Inc |
| Contact Person: | Robert Karr |
| Address: | 917 Diamondhead Drive, Lawrence, Kansas 66049 |
| Phone Number: | (860) 938-2315 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2010 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Business Services (Unclassified) |
| SIC Code: | 7389 |
| NAICS Code: | 561499 |
| Share This Business: |
Mencuro Therapeutics Inc was started in 2010 to provide professional Business Services (Unclassified) under the SIC code 7389 and NAICS code 561499. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Robert Karr for inquiries that concern Mencuro Therapeutics Inc by calling the company number (860) 938-2315, as your correspondence is most welcome. Additionally, the physical location of the single location of Mencuro Therapeutics Inc can be found at the coordinates 38.965122,-95.327616 as well as the street address 917 Diamondhead Drive in Lawrence, Kansas 66049.
For its online presence, you may visit Mencuro Therapeutics Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.